Sanofi-Aventis sues generic drug makers over Uroxatral

WILMINGTON, Del. Sanofi-Aventis has sued a cluster of generic drug manufacturers including Teva, Actavis and Barr over its drug Uroxatral, indicated for treating prostate gland enlargement, according to Bloomberg.

The company states that the generic manufacturers are infringing on two U.S. patents, with their plans to market a generic version. Prostate enlargement usually occurs in men over 40, and about half of all men in their 60s have some related symptoms, according to Sanofi’s Web site.

Also sued were: Aurobindo Pharma, Mylan, Par, Ranbaxy, Sun, and Torrent.